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Abstract- Malignant brain tumours are one of the most 
relevant causes of morbidity and mortality across a wide 
range of individuals. Malignant glioma is the most 
common intra axial tumor in the adult. Many researches 
on this theme  brought advances in the knowledge of 
gliomas biology and pathogenesis and to the development 
of new agents for targeted molecular therapy. Recent 
studies focused on either tumor metabolism analysis or 
epigenetic regulation in the pathogenesis or maintenance 
of brain tumors. This Review summarizes these 
developments analyzing molecular pathology and possible 
further developments for targeted therapies. 
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I.INTRODUCTION 
 
Astrocyticgliomas  are  the  most  common  primary  
brain cancer  [1],  with  an incidence  of  3–5  per  100  
000 people each year [2].  Gliomas  occur  in  all  age  
groups, but  are  most prevalent  in  adults  over  45  
years  of age [3].  
Tumors grading is made according to  WHO 
consensus-criteria, in which 4 classes are described, 
according to malignant behaviour taking into 
consideration histological features and  genetic 
alterations [4].  
 Grade I tumors are biologically benign and 
total removal leads to recovery;  
 Grade II tumors are low-grade malignancies 
that may follow long clinical courses, but 
early diffuse infiltration of the surrounding 
brain renders them often not totally resectable;  
 Grade III tumors exhibit aggressive behaviour 
characterized  by increased anaplasia and 
mithosys  over grade II tumors; due to this 
biological pattern; these tumors have often a 
quick progression 
 Grade IV tumors, also known as 
glioblastomamultiforme (GBM), exhibit more 
advanced features of malignancy, including 
vascular proliferation and necrosis, often 
refractory to radiotherapy or chemotherapy 
On the basis of clinical presentation, GBMs have been 
further subdivided into primary or secondary GBM  
 
 
 
 
 
 
subtypes. Primary GBMs account for the great majority 
of GBM cases in elderly patients, while secondary 
GBMs are quite rare and tend to occur in younger 
patients (often below the 45 years old). Primary GBM 
presents ex novo, with no evidence of prior symptoms 
or preexistant low grade glioma. Concerning secondary 
GBMs, the main event is  progressive transformation of 
lower grade astrocytomas in malignant neoplasms. It 
has been described that up to 70% of grade II gliomas  
progress to  grade III/IV Astrocytomas  within 5–10 yr 
from diagnosis. 
Despite different ethiopathogenesis, these two 
categories, are not distinguishable on hystopathological 
bases or clinical behaviour. 
One of the most relevant hypothesis concerning 
secondary GBMs, is related to the possibility of 
successive acquisition of genetic alterations. This 
hypothesis was proven analyzing selected genetic 
changes in low grade glioma (LGG), and the presence 
of the same alterations plus others in in high grade 
glioma (HGG). Thus the role of specific genetic 
alteration is supposed to be involved in malignant 
progression.  
Considering grade II, III and IV gliomas, the common 
behaviour is characterized by  invasiveness, thus 
surgery alone would be not sufficient as curative 
treatment [5]. The only life-prolonging treatment 
proven to be effective, consists of the association 
between radiant therapy and Chemoterapy with the 
alkilating agent called Temozolamide (TMZ). Despite 
this, prognosis remains poor with a reported median 
survival  of 14.6 months and a 2-year survival rate of 
26.5% [6,7].Tumor recurrence has been observed after  
6.9 months (mean) [6], resulting in a median patient 
survival of just 12–15 months following diagnosis [8].  
In order to improve survival, in combination with RT 
and/or cytotoxic chemotherapy, many targeted drugs 
were evaluated. In this review, we would like to remark  
important findings regarding the unique biology of this 
cancer, considering a neuroscience perspective, 
focusing on how these insights have influenced latest 
clinical trials and the search for further  treatment 
options. 
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II.  METHODOLOGY 
  
       A literature search using PubMed MEDLINE 
database has been performed. The search terms 
“genetics and glioma”, were combined with the 
following terms: “IDH, metilation, therapy”.  
 
 
III. DISCUSSION 
 
A.GENETIC ALTERATION IN GLIOMA 
A.1 Cell cycle dysregulation. RB and P53 pathway 
The RB and p53 pathways involved in regulation  of 
the G1-to-S-phase transition, are major targets of 
inactivating mutations in GBM. The absence of this 
regulatory system leads to an excessive and  
inappropriate cell division. This is caused by 
constitutively active mitogenic signaling effectors, 
such as phosphoinositide 3′-kinase (PI3K) and 
mitogen-activated protein kinase (MAPK).  
 
A.1.1 The Rb pathway 
The Rb1 gene, which maps on chromosome 13q14, is 
mutated in 25% of HGG and the loss of 13q is 
characteristic of transition from low-grade to 
intermediate-grade gliomas [9].  
The importance of the inactivation of the RB pathway 
in glioma progression is evidenced by the near-
universal and mutually exclusive alteration of RB 
pathway effectors and inhibitors in both primary and 
secondary GBM [10, 11]. However, many in vitro and 
in vivo assays showed  that the neutralization of this 
pathway alone is insufficient to subvert cell cycle 
control, thus not sufficient to cause cellular 
transformation. This is remarkable since  other cycle 
regulation pathways interfere preventing gliomagenesis 
[12-14]. 
 
A.1.2 The p53 pathway 
The p53 pathway is nearly invariably altered in 
sporadic (ex novo) GBMs: loss of p53, through either 
point mutations that prevent DNA binding or loss of 
chromosome 17p, is a frequent and early event in the 
pathological progression of secondary GBM [15, 16].  
The importance of p53 in gliomagenesis is also 
demonstrated by the increased incidence of gliomas in 
Li-Fraumeni syndrome, which is characterized by 
germline p53 mutations.  
Amplification of the p53 antagonists MDM2 and 
MDM4have also been found in distinct subsets of Tp53 
intactGBMs, as well as mutations and/or deletions 
inthe CDKN2A second locus that encodes p14ARF 
which is a regulator of p53. 
 
A.2 RTKs 
The Epidermal Growth Factor and platelet-derived 
growth factor (PDGF) pathways play an important role 
in gliomagenesis. Recently targeted therapy against 
these signalling are under basic and clinical 
investigation. 
 
A.2.1 EGFR 
The EGFR is a transmembrane glycoprotein that 
constitutes one of four members of the ErbB family of 
tyrosine kinase receptors. EGFR is activated by 
interaction with ligand to the extracellular domain, 
leading to receptor dimerization and subsequent 
activation of tyrosine kinases in the intracellular 
domain. This results in the stimulation of other 
downstream signaling effectors including PI3K, Akt, 
Ras, and mitogen-activated protein kinases (MAPK). 
All these pathways are involved in cell proliferation, 
survival, migration, and apoptosis[17].  
Approximately 40% of GBMs shows EGFR gene 
amplification and overexpression 
[18,19].Amplification of the EGFR gene is often 
associated with a mutation that encodes for a truncated 
form of the receptor, known as EGFR variant vIII 
(EGFRvIII), lacking  the extracellular binding domain 
and leading to constitutive activation of tyrosine 
kinases [20, 21]. Expression of EGFRvIII correlates 
with poor survival in GBM patients [22] and promotes 
glioma cell migration [23], tumor growth, invasion, 
survival [24] and angiogenesis [25]. Furhtermore, 
EGFRvIII causes enhanced apoptosis resistance. 
Activated EGFR is also related to  radio-and chemo-
resistance in GBM cells [26].  
A large number of therapeutic targets have been 
analyzed in order to block the EGFR signaling 
pathways, including monoclonal antibodies cetuximab, 
and TKIs gefitinib, erlotinib and lapatinib. However, 
the use of EGFR inhibitors, erlotinib and gefitinib, as 
single agents in patients with progressive GBM has 
shown no significant survival benefit [27]. 
 
A.2.2 PDGF receptor (PDGFR) 
In addition to the EGFR signaling axis, PDGFRα and 
its ligands, PDGF-A and PDGF-B, are represented in 
gliomas, especially in HGG. Concerning expression of 
PDGFRβ, high levels were reported in proliferating 
endothelial cells of GBM [28]. PDGF-C and PDGF-D, 
which require proteolytic cleavage to be activated, are 
also frequently expressed in glioma cell lines and in 
GBM tissues [29]. In contrast to the pathway of  
EGFR; amplification or rearrangement of PDGFRα is a 
less common event. This justifies that oncogenic 
deletion mutation of PDGFRα (loss of exons 8 and 9) 
have been rarely described [30]. 
Although rare, this mutation has a behaviour  similar to 
EGFRvIII variation: PDGFRα is constitutively active 
and enhances tumorigenesis. Considering the 
tumoralcoexpression of PDGF and PDGFR, the main 
hypothesis considers autocrine and paracrine loops as 
the main way to favour oncologic transformation. 
Supportive evidence for a paracrine circuit started by 
PDGF-B secretion were related to glioma angiogenesis. 
This has been demonstrated through stimulation of 
endothelial cells displaying PDGFRβ, in part, to 
express VEGF [31].On this findings an orally active 
kinase inhibitor of the 2-phenylaminopyrimidine class 
such as STI571 (imatinibmesylate) proved to be a 
potent inhibitor of these oncogenic loops [32, 33]. This 
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drug combined with hydroxyurea in a phase II study, 
achieved durable anti-tumor activity in some patients 
with recurrent GBM [34]. Imatinib alone, proved to 
have minimal activity in malignant glioma [35]. 
 
A.3 Mitogenicsignaling pathways 
Enhanced RTK signalling, whether driven by somatic 
mutagenesis or other stimuli, seems to play a relevant 
role  in many HGG. These effects are probably 
mediated through oncogenic PI3K–AKT–mTOR and 
Ras–MAPK signalling downstream.  
This is a remarkable event since it is  not infrequent to 
find molecular components in these downstream 
networks in HGG [36, 37]. The most common 
alteration is functional loss of the tumour suppressor  
gene pTEN, that is the primary negative regulator of 
PI3K–AKT–mTOR signalling [38, 39] .  
PTEN  is commonly mutated in 20%–40% of GBMs 
[40]. Thus, targeting the mTOR complex may represent 
a valuable therapeutic approach for GBM. Actually 
synthetic analogues of rapamycin (sirolimus), 
including temsirolimus, everolimus, and ridaforolimus 
are currently being tested in GBM. 
 
TABLE I 
 
GENETIC ALTERATION IN GLIOMA 
Cell 
cycle 
dysregul
ation 
RTKs Mitogenicsignalin
g pathways 
Rb1 
mutated 
in 25% 
of HGG; 
 
loss of 
13q  
transitio
n from 
LGG to 
intermed
iate-
grade 
gliomas 
EGFR gene 
amplification and 
overexpression40
% of GBMs  
PTENmutation  
20%–40% of 
GBMs 
p53ne
arly 
invariabl
y altered 
in ex 
novo 
GBMs; 
 
loss of 
p53 
early 
event in 
progress
ion of 
secondar
y GBM 
PDGF and 
PDGFRcoexpression
autocrine and 
paracrine loops 
determine oncologic 
transformation. 
 
PDGF-B glioma 
angiogenesis 
PI3K–AKT–
mTORsignallingco
stitutively 
activated by 
stimulation of 
RKTs and 
unsuppressed by 
PTEN 
 
 
B. ANGIOGENESIS 
GBMs are among the most highly vascular of all solid 
tumors. Microvascular hyperplasia consists of 
proliferating endothelial cells that emerge from normal 
parent microvessels as tufted microaggregates 
(glomeruloid bodies) accompanied by stromal 
elements, including pericytes and basal lamina [41]. 
Microvascular density, a measure of microvascular 
proliferation, is an independent prognostic factor for 
adult gliomas [42, 43]. Angiogenesis and its major 
regulator, VEGF, represents one of the most important 
therapeutic targets in GBM treatment. Several 
VEGF/VEGFR inhibitors have been recently 
developed, including bevacizumab, vatalanib, 
cediranib, sunitinib, sorafenib, vandetanib, and 
aflibercept. 
Bevacizumab was used in two independent studies as 
monotherapy for recurrent gliomas. These studies 
reported favorable 6-month progression-free survival 
rates of 42.6% [44] and 29% [45], significantly greater 
than the 18% derived from TMZ use [46]. These 
studies also showed a reduction in peritumoraledema, 
allowing a reduction of the corticosteroid dose for 
symptoms relieve/control [45]. These successes 
promoted further trials looking at the benefits of adding 
bevacizumab to radiation and TMZ [47-49]. In 
literature, there are 114 registered clinical trials using 
bevacizumab in patients with glioma, typically in 
combination with other treatment modalities. 
Unfortunately, the benefit of anti-angiogenic therapies 
so far remains limited [50]. This may be due to  the 
vascularization supplies of the growing tumor. 
Moreover, anti-angiogenic therapy showed to produce 
a more invasive and aggressive tumor cell phenotype, 
including increased expression of other proangiogenic 
factors [51], upregulation of pro-invasion proteins such 
as matrix metalloproteinases[51], activation of pro-
invasive signaling pathway such as the 
phosphatidylinositol 3-kinase (PI3K)- and Wnt-
signaling pathways [52]. This leads also to an increase 
in tumor hypoxia by upregulation of hypoxia-inducible 
factor 1a (HIF1a) [52]. 
 
C. EPIGENETIC: REGULATION OF GENE 
EXPRESSION THAT ALTERS THE RESPONSE TO 
TREATMENT   
Patients with 6-O-Methylguanine-DNA 
Methyltransferase (MGMT) promoter methylation who 
received TMZ and radiation therapy showed a median 
survival time of 21.7 months compared with 12.7 
months for those who had unmethylated MGMT [53]. 
Two-year survival was 46% with MGMT methylation, 
compared with 13.8% without MGMT methylation 
[53].   
Increased activity of the MGMT gene inhibits the 
effects of TMZ, the standard alkylating 
chemotherapeutic agent used to treat gliomas[53] and 
explains why some patients fail to benefit from this 
treatment. In individuals resistant to TMZ treatment, 
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the MGMT promoter [53,54] isunmethylated and 
transcription of the gene provides sufficient protein to 
counteract the effects of TMZ. Conversely, patients 
with a methylated MGMT promoter do not generate 
the protein and, therefore, are more sensitive to TMZ 
therapy, particularly if combined with radiation [53].  
The recognition that this specific epigenetic 
modification dramatically alters the potency of a 
commonly used chemotherapeutic was an important 
assumption, as it allows a patient-tailored treatment. 
Unfortunately, the lack of an effective alternative 
treatment didn’t gave many other options in TMZ 
refractory patients. It is tempting to speculate that 
MGMT-mediated DNA repair may itself be considered 
a potentially valuable therapeutic target for the 50% of 
patients that express the MGMT gene [55].  
 
D. INTEGRATED GENOMICS AND SUBSEQUENT 
ADVANCES 
Integrated genomic analysis has also facilitated the 
identification and characterization of additional genes 
involved in glioma pathogenesis. Recently, missense 
mutations in isocitrate dehydrogenase 1 (IDH1) were 
found in a significant number of GBMs that tend to 
occur mostly in younger patients with more protracted 
clinical courses [56]. These point mutations are 
restricted exclusively to the R132 residue in the active 
site region of the protein in which they disrupt 
hydrogen binding with its substrate [56, 57]. Curiously, 
a separate group of gliomas harbour mutations in the 
IDH1 homologue IDH2 at the analogous residue 
(R172). Further investigations have shown that 
mutations in IDH1 and IDH2 are present in high 
proportions of grade II and III astrocytic and 
oligodendroglial tumours (72–100%) along with 
secondary GBMs (85%), but are largely absent in 
primary GBMs (5%) [57, 58] .  
Additionally, IDH mutations are associated with other 
genomic abnormalities that are typically seen in LGG, 
such as Tp53 mutation and 1p/19q deletion; they are 
also mutually exclusive with EGFR amplification and 
chromosome 10 loss, and multivariate analysis 
suggests that they are independent favourable 
prognostic markers [57, 59]. These findings suggest 
that, although IDH mutations probably contribute to 
the early evolution of LGG (including those that 
subsequently progress to higher grade lesions), they 
seem to have no role in the underlying biology of ex 
novo GBM. These findings emphatize the 
pathogenethic differences between these two broad 
diagnostic categories.  
The mechanisms related  to  mutations in IDH genes 
and the induction of gliomagenesis are still largely 
unknown. However, a recent study demonstrated that 
loss of IDH1 function through point mutation induces 
hypoxia inducible factor 1α (HIF1α) [60]. This is  a 
component of the hypoxia-responsive transcription 
factor complex that has been proved to be involved in 
angiogenesis and tumour growth [61]. By contrast, 
another recent report has shown that mutant IDH1 
proteins exhibit a gain-of-function phenotype by 
generating R-2-hydroxyglutarate (2HG), a toxic 
metabolite associated with an increased risk of 
malignant brain tumours in patients with inherited 
errors of 2HG metabolism [62].  
Although much remains to be analyzed, the 
identification of IDH mutations in diffuse gliomas, and 
more recently in acute myeloid leukaemia [63], 
provided new potential therapeutic targets and 
emphasized the increasingly compelling link between 
cancer biology and basic metabolic processes. 
 
 
 
TABLE II 
 
IDH1 and IDH2 MUTATION 
AstrociticangOligodendroglial 
tumours (WHO II & III) 
 
72–100% 
secondary GBMs 85% 
primary GBMs 5% 
 
TABLE III 
 
IDH1 MUTATION 
Loss of function Gain of function 
HIF1αangiogenesis 
and tumour growth 
2HGincreased histone 
methylationblocks to 
cellular  differentiation, 
andtumorigenesis 
 
 
E. GENETIC AND MOLECULAR ALTERATIONS 
RESULT IN CHANGES IN CELLULAR 
METABOLISM 
It is becoming increasingly evident that at least some of 
these genetic and molecular alterations result in 
changes in cellular metabolism. GBMs frequently 
exhibit increased glucose consumption and lactate 
production in the presence of oxygen, known as 
Warburg effect [64] . Activation of PI3K/AKT in GBM 
cell lines leads to increased glucose uptake and 
glycolysis [64-66] .  
Pyruvate kinase M2 (PKM2), an enzyme that plays a 
critical role in the glycolytic pathway, is an example of 
a metabolic enzyme that can affect histone 
modifications. In EGFR driven glioblastoma, PKM2 
translocates to the nucleus and phosphorylates histone 
3 at threonine 11 (H3-T11) [67]. This causes 
dissociation of HDAC3 from the Cyclin D1(CCND1) 
and c-MYC promoters and subsequent histone 
acetylation, leading to transcription of CCND1 and c-
MYC, and subsequent cell proliferation [67, 68] . 
More recently, the NADP+ -dependent enzyme IDH1 
was found to be mutated in ~70% of grade II and grade 
III astrocytomas and oligodendrogliomas, and 
secondary GBMs [57, 69, 70].  
How mutations in IDH1 result in DNA methylation in 
gliomas is not entirely known. One hypothesis (Fig. 3) 
is that mutant IDH1 catalyzes the production of 2-
hydroxyglutarate (2-HG) from a-ketoglutarate (a-KG). 
The Jumonji C family of histone lysine demethylases 
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(KDMs) and the TET group of DNA hydroxylases are 
a-KG-dependent dioxygenases. 2-HG, structurally 
similar to a-KG [71, 72],  is thought to inhibit a-KG-
dependent dioxygenase enzymes. Inhibition of these 
enzymes may result in increased histone methylation 
marks and DNA methylation contributing to G-CIMP 
responsible for global changes to DNA methylation, 
inhibition of histone lysine demethylases, blocks to 
cellular  differentiation, and ultimately, tumorigenesis 
[73-76]. 
These observations advocates the possibility that 
inhibiting IDH mutants might reverse their tumorigenic 
effects [77] and that the design of effective inhibitors 
would need to take into account the complex 
downstream effects of IDH mutations.Recently, to 
assess this therapeutic possibility in the glioma context, 
Rohle et al. [78] used AGI-5198, a small molecule 
inhibitor of the most common IDH mutation in 
gliomas, IDH1-R132H. Treatment of an 
oligodendroglioma cell line harboring an endogenous 
IDH1-R132H mutation with this inhibitor reduced 
growth in soft agar by 40%–60% and impeded the 
growth of xenograft tumors derived from that cell line 
in mice.  
Analysis of these tumors showed a reduction in 
proliferative markers but no change in apoptosis, 
suggesting that the altered tumor growth was due to 
failure to proliferate as opposed to cell death. 
Following treatment, several genes involved in glial 
differentiation were upregulated and found to have lost 
repressive histone marks H3K9me3 and H3K27me3 at 
their promoters, implying that the mutant IDH1 
inhibitor is capable of erasing histone modifications 
that influence gene expression. This study 
demonstrated that, in this model, targeting mutant 
IDH1 can impair glioma growth in vivo and this 
growth inhibition is linked to changes in 
differentiation. 
 
TABLE IV 
 
BIOLOGICAL TARGET THERAPY 
RTKs PTEN 
pathway 
Angiogene
sis 
IDH1 
Erlotinib, 
Gefinitib 
EGFR; 
 
Imatinib+Hyd
roxyurea 
PDGF 
Temsirolimus, 
everolimus, 
ridaforolimus
mTOR 
Bevacizum
av 
VEGF 
AGI-
5198
ID
H1-
R132
H 
 
 
IV. CONCLUSION 
 
Gliomas remain one of the most challenging cancers to 
treat, as demonstrated by the poor improvements in 
patients survival. This may be partially connected to 
the fact that current treatment approaches are similar to 
the ones used for other solid-tumors. This could be 
counter-productive due to the lack of consideration of 
the unique biology of gliomas.Despite the strong 
rationale of clinical trials with genetic targets, most 
studies have shown very modest results. The negative 
results reported in the majority of published clinical 
studies may be explained, at least in part, by single-
targeted approaches, which may be somehow limited 
by such factors as tumor heterogenity and genetic 
instability. Heterogenity of the GBM cell population, 
which includes expression of cell surface receptors, as 
well as proliferative and angiogenic potential, might be 
attributed to morphological and epigenetic plasticity. 
On the other hand, there is also evidence for the 
coexistence of genetically divergent tumor cell clones 
within tumors. So far, if multiple oncogenic processes 
are active in distinct tumor subpopulations, single-
targeted therapies may provide limited effects. 
Furthermore, GBM cells may exhibit significant 
genetic instability, possibly leading to resistance of 
single-targeted agents by switching to alternative 
molecular pathway. Recently, however, a new 
paradigm is emerging in cancer biology, represented by  
convergence of multiple metabolic pathways and 
epigenetic regulation. The complex connection 
between the metabolic state of a cancerous cell and its 
epigenetic machinery represents a novel mechanism,  
by which the normal control of cell 
proliferation/differentiation can be disrupted. 
Discovering the dynamics and intricacies of these 
processes may help us in developing a better 
understanding of gliomas, thus permitting  the 
knowledge of novel therapeutic targets to effectively 
fight these highly aggressive tumors. 
We suggest that new trends on HGG targeted therapies 
should not focus on a single genetic pathway, but 
should try to interact in different molecular 
pathways.We think that  HGG biology has many 
shortcuts and secret passages, not yet fully discovered. 
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